The new capital is expected to fund the company through 2029
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Company leadership is framing the move as transformational.
Subscribe To Our Newsletter & Stay Updated